TP53 and neoplasm: These results suggest that TP53 mutations are also associated with broader metabolic reprogramming in patient-derived tumors, highlighting the clinical relevance of targeting specific bioenergetic vulnerabilities in EAC, including the assessment of tumor microenvironment and extracellular metabolites.